OCULAR THERAPEUTIX, INC Increase (Decrease) in Contract with Customer, Liability
OCULAR THERAPEUTIX, INC (OCUL) reported Increase (Decrease) in Contract with Customer, Liability of -$128.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $0.00.
- OCULAR THERAPEUTIX, INC increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $0.00.
- OCULAR THERAPEUTIX, INC increase (decrease) in contract with customer, liability for the quarter ending 2025-06-30 was -$64.00K.
- OCULAR THERAPEUTIX, INC increase (decrease) in contract with customer, liability for the quarter ending 2025-03-31 was -$64.00K.
- OCULAR THERAPEUTIX, INC increase (decrease) in contract with customer, liability for fiscal 2025 was -$128.00K.
- OCULAR THERAPEUTIX, INC increase (decrease) in contract with customer, liability for fiscal 2024 was -$262.00K, a 161.36% decline from fiscal 2023.
- OCULAR THERAPEUTIX, INC increase (decrease) in contract with customer, liability for fiscal 2023 was $427.00K, a 55.66% decline from fiscal 2022.
- OCULAR THERAPEUTIX, INC increase (decrease) in contract with customer, liability for fiscal 2022 was $963.00K, a 3.70% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $0.00 derived: sum of 2 quarters · filed 2026-02-05 | -$64.00K derived: sum of 3 quarters · filed 2026-08-03 | -$128.00K 10-K · filed 2026-02-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$64.00K derived: sum of 2 quarters · filed 2026-08-03 | -$128.00K 10-Q · filed 2025-11-04 | -$190.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$64.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$128.00K 10-Q · filed 2026-08-03 | -$190.00K derived: sum of 3 quarters · filed 2026-08-03 | -$269.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$64.00K 10-Q · filed 2026-05-05 | -$126.00K derived: sum of 2 quarters · filed 2026-05-05 | -$205.00K derived: sum of 3 quarters · filed 2026-05-05 | -$267.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | -$141.00K derived: sum of 2 quarters · filed 2026-02-05 | -$203.00K derived: sum of 3 quarters · filed 2026-02-05 | -$262.00K 10-K · filed 2026-02-05 |
| 2024-09-30 | -$79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$141.00K derived: sum of 2 quarters · filed 2025-11-04 | -$200.00K 10-Q · filed 2025-11-04 | -$324.00K derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-06-30 | -$62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$121.00K 10-Q · filed 2025-08-05 | -$245.00K derived: sum of 3 quarters · filed 2026-02-05 | -$376.00K derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-03-31 | -$59.00K 10-Q · filed 2025-05-05 | -$183.00K derived: sum of 2 quarters · filed 2026-02-05 | -$314.00K derived: sum of 3 quarters · filed 2026-02-05 | $528.00K derived: sum of 4 quarters · filed 2026-02-05 |
| 2023-12-31 | -$124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | -$255.00K derived: sum of 2 quarters · filed 2026-02-05 | $587.00K derived: sum of 3 quarters · filed 2026-02-05 | $427.00K 10-K · filed 2026-02-05 |
| 2023-09-30 | -$131.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $711.00K derived: sum of 2 quarters · filed 2024-11-14 | $551.00K 10-Q · filed 2024-11-14 | $378.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $842.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $682.00K 10-Q · filed 2024-08-07 | $509.00K derived: sum of 3 quarters · filed 2025-03-03 | $456.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$160.00K 10-Q · filed 2024-05-07 | -$333.00K derived: sum of 2 quarters · filed 2025-03-03 | -$386.00K derived: sum of 3 quarters · filed 2025-03-03 | -$508.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$173.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$226.00K derived: sum of 2 quarters · filed 2025-03-03 | -$348.00K derived: sum of 3 quarters · filed 2025-03-03 | $963.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | -$53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$175.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.14M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$122.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.19M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $1.31M 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $1.00M 10-K · filed 2024-03-11 | |||
| 2020-12-31 | $12.00M 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |